Boston Scientific Corp. reported first‑quarter 2026 results on April 22 2026, posting net sales of $5.203 billion, an 11.6% year‑over‑year increase from $4.663 billion in Q1 2025. The company’s basic earnings per share rose to $0.90, up from $0.45 in the same quarter a year earlier, while adjusted EPS reached $0.80, the high end of the $0.78–$0.80 guidance range and a $0.05 increase over the $0.75 adjusted EPS reported in Q1 2025.
Revenue growth was driven by strong demand in the cardiovascular and electrophysiology segments. The cardiovascular business grew 13.5% reported and 11.2% organic, while the MedSurg segment grew 7.8% reported and 5.7% organic. Margin pressure, however, weighed on the results: adjusted operating margin was 28.0%, and adjusted gross margin fell 100 basis points to 70.5% due to tariffs and inventory charges related to product discontinuations such as the POLARx Cryoablation system.
"Our global team and the strength of our category leadership strategy enabled us to deliver solid results this quarter," said Mike Mahoney, chairman and chief executive officer. "We remain focused on executing our long‑term strategy and advancing our differentiated pipeline to drive meaningful impact for patients, physicians and hospital systems."
In light of the strong quarter, Boston Scientific revised its full‑year 2026 guidance, lowering reported revenue growth to a 7.0%–8.5% range from the previously expected 10.5%–11.5% and adjusted EPS to $3.34–$3.41 from $3.43–$3.49. Management cited unanticipated headwinds in the WATCHMAN and electrophysiology segments, as well as margin pressure from tariffs and inventory charges, as the primary reasons for the guidance cut.
"First quarter represented a solid quarter for Boston Scientific with total company organic sales growth of 9.4% versus our guidance range of 8.5% to 10%. First quarter adjusted EPS of $0.80 grew 6%, achieving the high end of our guidance range of $0.78 to $0.80 and Q1 adjusted operating margin was 28%.", Mahoney added on the earnings call.
Analysts noted the guidance cut as a sign of caution, with some adjusting their expectations for the remainder of the year. The earnings beat, however, underscored the company’s ability to maintain profitability amid competitive pressures and cost‑control initiatives.
revised_sentiment_rating
}
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.